Global Psoriasis Drugs Market Size study, by Class, Treatment (Topicals, Systemic, Biologics), Route of Administration (Oral, Parenteral), Distribution Channel, and Regional Forecasts 2022-2032

Global Psoriasis Drugs Market is valued at approximately USD 19.2 billion in 2023 and is projected to surge with a compelling CAGR of more than 10.80% during the forecast period 2024–2032. Psoriasis, a chronic and often debilitating autoimmune skin disease, is witnessing a transformative shift in treatment paradigms with the advent of innovative pharmaceutical interventions. Traditionally managed with topical steroids and phototherapy, the market is now embracing advanced biologics and systemic therapies that target the disease at a molecular level. These treatments have proven to drastically enhance patient outcomes, offering longer remission periods and improved quality of life. As healthcare providers increasingly move toward patient-centric strategies, the demand for customized and efficacious treatment regimens has bolstered investment in novel drug development, pushing the psoriasis drugs market into an accelerated growth trajectory.

The momentum in this market is primarily fueled by the rising prevalence of psoriasis globally, coupled with a growing awareness of its comorbidities such as cardiovascular diseases, diabetes, and depression. Moreover, pharmaceutical firms are actively engaged in extensive clinical trials and research collaborations to expand their product pipelines, particularly in the biologics segment. The growing adoption of targeted immunomodulators and biosimilars is opening lucrative avenues for both existing players and new entrants. However, market progression is challenged by the high cost of biologics, complex regulatory frameworks, and uneven access to advanced therapeutics across developing economies. These barriers, though substantial, are being gradually mitigated by policy reforms, generic competition, and advancements in drug delivery systems.

Another catalyst for market expansion is the increasing use of precision medicine and genomics to guide therapy choices. Personalized drug protocols based on genetic and immune profiling are becoming more feasible, driving efficacy and reducing side effects. Additionally, patients are gravitating toward oral therapies and minimally invasive biologics, steering pharmaceutical companies to shift focus toward developing parenteral-free formats and enhancing treatment compliance. The integration of digital therapeutics and remote monitoring tools is also beginning to reshape how chronic dermatologic diseases are managed, setting a new standard in patient engagement and adherence monitoring.

From a geographical perspective, North America dominates the psoriasis drugs landscape, supported by strong reimbursement policies, high disease burden, and robust R&D activities. The U.S. in particular remains the innovation hub with rapid biologic approvals and widespread access to advanced care. Europe follows closely, with countries like Germany and the UK contributing significantly due to favorable healthcare infrastructure and high biologic penetration. Meanwhile, the Asia Pacific region is poised for exponential growth owing to increasing awareness, improving access to healthcare, and rising prevalence of psoriasis in countries such as India, China, and Japan. Latin America and the Middle East & Africa are anticipated to demonstrate gradual yet promising growth with the introduction of biosimilars and expansion of healthcare coverage.

Major market player included in this report are:
• Johnson & Johnson Services, Inc.
• Novartis AG
• AbbVie Inc.
• Pfizer Inc.
• Eli Lilly and Company
• Amgen Inc.
• Bristol Myers Squibb
• Merck & Co., Inc.
• Sun Pharmaceutical Industries Ltd.
• UCB S.A.
• Takeda Pharmaceutical Company Limited
• Biocon Biologics Limited
• Boehringer Ingelheim International GmbH
• LEO Pharma A/S
• Galderma S.A.

The detailed segments and sub-segment of the market are explained below:

By Class
• TNF Inhibitors
• Interleukin Inhibitors
• PDE4 Inhibitors
• Others

By Treatment
• Topicals
• Systemic
• Biologics

By Route of Administration
• Oral
• Parenteral

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America
• Brazil
• Mexico

Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.